Apple's colorful mainstream flagship, starting at $749.
Report Claims iWatch Awaiting FDA Approval, Will Feature Blood Glucose and Sweat Sensors
It was reported earlier this month that Apple had met with the FDA in December to discuss a number of topics, with some suggesting that Apple might be laying some groundwork for the iWatch. However, a memo issued by the FDA noted that the dialogue merely revolved around its guidance on mobile apps and making sure that the technology industry and regulators are on the same page.
Laoyaoba also claims that the iWatch will come with a number of advanced health sensors, including those that measure heart rate, blood pressure, and blood glucose. Apple has also apparently developed an in-house sweat analysis sensor for the iWatch, which will all work with iOS 8's Health app to track various health metrics.
This information also contrasts a number of past reports that pointed to the iWatch focusing on more simple functionality to make the health-tracking experience more accessible to everyone. While Apple hired a number of personnel with expertise in fields like blood glucose monitoring, it has been noted that such technologies may not make it into the first-generation iWatch, which require a lengthy-approval process from the FDA and complex hardware integration.
Reports from the The Wall Street Journal and Reuters yesterday noted that Apple is also still trying to finalize specifications for the device. Notably, the Wall Street Journal report suggested that the iWatch will ship in "multiple versions", while the Reuters report said that the device will sport a 2.5-inch screen and feature wireless charging and pulse sensing capabilities.
The iWatch is expected to be revealed and launched in October, which was a date reported earlier this month by Re/code.